A new biological signal in oncology

eccDNA, an Emerging Biomarkerfrom Cancer Biology to Clinical Practice

CLEOMICS is pioneering a proprietary liquid biopsy solution that combines extrachromosomal circular DNA (eccDNA) with artificial intelligence, enabling earlier detection and more precise monitoring of cancer.

Request a Meeting Explore the technology

eccDNA: A distinct molecular signal
AI: Proprietary analytical engine
UPVD: Academic-grade foundations

Visualization of extrachromosomal circular DNA and AI network

Liquid biopsyeccDNAPrecision oncologyAI diagnosticsCell-free DNAGenomicsTreatment monitoringEarly detectionLiquid biopsyeccDNAPrecision oncologyAI diagnosticsCell-free DNAGenomicsTreatment monitoringEarly detectionLiquid biopsyeccDNAPrecision oncologyAI diagnosticsCell-free DNAGenomicsTreatment monitoringEarly detection

Technology

A liquid biopsy solution based on extrachromosomal circular DNA.

CLEOMICS combines specialized molecular biology, next-generation sequencing and proprietary AI to read a signal that has remained largely invisible to conventional liquid biopsy.

Circulating circular DNA in blood plasma

Sample

A single routine blood draw

01
A unique molecular signal
We focus on extrachromosomal circular DNA, small circular fragments of DNA that circulate in blood and carry information that linear cell-free DNA does not.
02
Wet-lab and sequencing
A specific molecular biology workflow isolates, amplifies and sequences eccDNA from a routine blood draw, with high specificity for the circular signal.
03
Proprietary AI
Our analytical engine learns the eccDNA fingerprint, separates tumor-derived signal from background, and turns raw sequencing data into clinically meaningful insights.

AI engine

From sequencing reads to decision-grade insight.

Our algorithms are trained specifically on the biology of extrachromosomal circular DNA: structural features, junction patterns, abundance dynamics. They were designed from the ground up for this signal, not adapted from mutation-calling pipelines.

Specialized representation of eccDNA structure
Robust separation of tumor signal from biological noise
Designed for longitudinal monitoring, not just static snapshots

Scientific rationale

Why eccDNA matters in oncology.

Extrachromosomal circular DNA is no longer a curiosity. It is now seen as a biologically meaningful signal, and one that current diagnostics largely miss.

01
A different molecule
Most liquid biopsy approaches focus on point mutations or linear cell-free DNA fragments. eccDNA is a structurally distinct molecule with its own biology and its own information content.
02
An emerging hallmark of cancer
eccDNA is increasingly recognized as a meaningful player in cancer biology, associated with oncogene amplification, tumor heterogeneity and treatment resistance.
03
An untapped diagnostic layer
Because it carries information that linear DNA does not, eccDNA opens a complementary diagnostic layer, one we believe will be central to next-generation precision oncology.

Clinical relevance

Designed with the clinical practice in mind.

From a single blood draw to decision-grade information, without the limitations of invasive tissue biopsy.

Detection

Identify cancer signal, earlier.

By targeting a distinct molecular fingerprint, eccDNA-based liquid biopsy aims to capture disease signal that complements existing modalities.

Monitoring

Follow how a tumor responds.

Longitudinal eccDNA profiling is designed to track changes during treatment, providing a dynamic readout of biology rather than a single snapshot.

Stratification

Inform precision decisions.

Structural and quantitative eccDNA features can enrich the data clinicians use to choose, adapt and evaluate therapy in a precision medicine framework.

For oncology teams

We're actively building scientific and clinical partnerships around eccDNA in oncology.

Talk to our team

Our story

Born from rigorous science.Built for clinical impact.

1Origin
Academic foundations
The scientific basis of CLEOMICS originates from research conducted within a UPVD / CNRS / IRD laboratory, where eccDNA was demonstrated to be detectable, sequenceable and analyzable.
2Translation
From discovery science to oncology
Marie Mirouze's research contributed to establishing eccDNA as a measurable biological signal. CLEOMICS translates this expertise into human oncology applications.
3Today
A focused MedTech company
CLEOMICS is building a proprietary liquid biopsy solution combining wet-lab know-how, sequencing and AI, engineered to make eccDNA clinically actionable.
4Tomorrow
Toward precision oncology at scale
Our ambition is a category of diagnostics that helps detect cancer earlier and follows its biology in real time, throughout the treatment journey.

Team

A team built at the intersection of biology, medicine and AI.

CLEOMICS brings together complementary expertise required to take a scientifically grounded discovery and turn it into a credible MedTech company.

Philippe Outrebon

CEO & CO-FOUNDER

Dr Marie Mirouze

UPVD/IRD/CNRS ECCDNA EXPERT

Dr Sophie Binay

STRATEGY & CLINICAL DEVELOPMENT

Dr Nassera Chalabi

PARTNERSHIPS & MEDICAL AFFAIRS

STRATEGIC BOARD

Marc Perotto

CEO WIDIP

Philippe Garnier

CEO EMVISTA

Celia Belline

CEO CILCARE

Ecosystem

Rooted in a strong academic and research ecosystem.

CLEOMICS builds on long-standing scientific collaborations and a research heritage at the intersection of genomics, molecular biology and computational sciences.

Scientific foundations

Built on peer-reviewed science.

Our approach is grounded in a growing body of literature on extrachromosomal circular DNA, from foundational characterization to its emerging role in cancer biology.

A complete list of references and ongoing scientific work is shared on request as part of partnership and investment discussions.

Request a meeting

eccDNA, an Emerging Biomarkerfrom Cancer Biology to Clinical Practice

A liquid biopsy solution based on extrachromosomal circular DNA.

A unique molecular signal

Wet-lab and sequencing

Proprietary AI

From sequencing reads to decision-grade insight.

Why eccDNA matters in oncology.

A different molecule

An emerging hallmark of cancer

An untapped diagnostic layer

Designed with the clinical practice in mind.

Identify cancer signal, earlier.

Follow how a tumor responds.

Inform precision decisions.

We're actively building scientific and clinical partnerships around eccDNA in oncology.

Born from rigorous science.Built for clinical impact.

Academic foundations

From discovery science to oncology

A focused MedTech company

Toward precision oncology at scale